









市场行情
/
股票
/
nasdaq-adct
/

ADC Therapeutics SA

ADCT

3.500USD

-0.200-5.41%

收盘 12/23, 16:00（美东）报价延迟15分钟

394.19M总市值

亏损市盈率 TTM



ADC Therapeutics SA

3.500

-0.200-5.41%

概览公司财务分析

概览

公司

财务

分析

关于 ADC Therapeutics SA 公司

ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.

ADC Therapeutics SA简介



公司代码ADCT

公司名称ADC Therapeutics SA

上市日期May 15, 2020

CEOMallik (Ameet)

员工数量263

证券类型Ordinary Share

年结日May 15

公司地址Biopole

城市EPALINGES

上市交易所NASDAQ OMX NASDAQ Basic NYSE

国家Switzerland

邮编1066

电话41216530200

网址https://adctherapeutics.com/

公司代码ADCT

上市日期May 15, 2020

CEOMallik (Ameet)

ADC Therapeutics SA公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Ron R. Squarer

Non-Executive Chairman of the Board

1.58M

+1.60%

Mr. Ameet Mallik

Chief Executive Officer, Director

1.31M

-15.07%

Mr. Mohamed Zaki, M.D., Ph.D.

Chief Medical Officer

601.26K

-6.39%

Mr. Jose (Pepe) Carmona

Chief Financial Officer

351.57K

-13.15%

Mr. Peter J. Graham

Chief Legal and Compliance Officer and Secretary

311.53K

-13.71%

Dr. Peter Hug, Ph.D.

Non-Executive Vice Chairman of the Board, Lead Independent Director

180.50K

+26.54%

Ms. Viviane Monges

Non-Executive Independent Director

134.98K

+38.35%

Dr. Victor Sandor, M.D.

Non-Executive Independent Director

99.40K

+38.06%

Mr. Robert W. (Bob) Azelby

Non-Executive Independent Director

55.26K

+98.35%

Mr. Timothy P. (Tim) Coughlin, CPA

Director

40.00K

名称

名称/职务

职务

持股

持股变动

Mr. Ron R. Squarer

Non-Executive Chairman of the Board

1.58M

+1.60%

Mr. Ameet Mallik

Chief Executive Officer, Director

1.31M

-15.07%

Mr. Mohamed Zaki, M.D., Ph.D.

Chief Medical Officer

601.26K

-6.39%

Mr. Jose (Pepe) Carmona

Chief Financial Officer

351.57K

-13.15%

Mr. Peter J. Graham

Chief Legal and Compliance Officer and Secretary

311.53K

-13.71%

Dr. Peter Hug, Ph.D.

Non-Executive Vice Chairman of the Board, Lead Independent Director

180.50K

+26.54%

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月18日周二

持股股东

股东类型

持股股东

占比

Redmile Group, LLC

12.65%

HPWH TH AG

7.00%

Point72 Asset Management, L.P.

6.57%

Prosight Capital

6.03%

OrbiMed Advisors, LLC

4.77%

其他

62.99%

持股股东

占比

Redmile Group, LLC

12.65%

HPWH TH AG

7.00%

Point72 Asset Management, L.P.

6.57%

Prosight Capital

6.03%

OrbiMed Advisors, LLC

4.77%

其他

62.99%

股东类型

持股股东

占比

Investment Advisor/Hedge Fund

21.83%

Hedge Fund

16.53%

Corporation

8.80%

Investment Advisor

8.55%

Research Firm

6.43%

Individual Investor

4.96%

Private Equity

4.77%

Bank and Trust

0.39%

Venture Capital

0.07%

其他

27.66%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

191

72.94M

63.83%

-1.48K

2025Q3

203

72.94M

76.75%

+266.41K

2025Q2

196

72.67M

64.60%

+13.50M

2025Q1

198

59.17M

80.56%

-20.65M

2024Q4

201

60.84M

78.41%

+1.63M

2024Q3

204

59.22M

80.70%

+2.20M

2024Q2

196

56.12M

64.88%

+18.35M

2024Q1

159

35.17M

75.47%

-27.30M

2023Q4

158

34.44M

76.49%

-6.23M

2023Q3

162

40.67M

76.05%

-5.62M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Redmile Group, LLC

15.67M

13.93%

Jun 30, 2025

HPWH TH AG

8.67M

7.71%

-1.12M

-11.42%

May 15, 2025

Point72 Asset Management, L.P.

7.76M

6.9%

+7.76M

Jun 30, 2025

Prosight Capital

10.47M

9.3%

+924.77K

+9.69%

Jun 30, 2025

OrbiMed Advisors, LLC

5.91M

5.25%

-61.10K

-1.02%

Jun 30, 2025

Oaktree Capital Management, L.P.

4.02M

3.57%

+4.02M

Apr 25, 2024

BlackRock Institutional Trust Company, N.A.

4.06M

3.6%

-442.92K

-9.85%

Jun 30, 2025

Morgan Stanley & Co. LLC

2.99M

2.66%

+33.76K

+1.14%

Jun 30, 2025

Nantahala Capital Management, LLC

2.27M

2.01%

+2.27M

Jun 30, 2025

Auven Therapeutics General LP

2.23M

1.98%

-4.10M

-64.75%

Apr 23, 2024

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.06%

SPDR S&P International Small Cap ETF

0.04%

iShares Biotechnology ETF

0.03%

iShares Russell 2000 Growth ETF

0.02%

ProShares UltraPro Russell2000

0.01%

ProShares Hedge Replication ETF

0.01%

Proshares Ultra Russell 2000

0.01%

Global X Russell 2000 ETF

0.01%

iShares Russell 2000 ETF

0.01%

Fidelity Enhanced Small Cap ETF

iShares Micro-Cap ETF

占比0.06%

SPDR S&P International Small Cap ETF

占比0.04%

iShares Biotechnology ETF

占比0.03%

iShares Russell 2000 Growth ETF

占比0.02%

ProShares UltraPro Russell2000

占比0.01%

ProShares Hedge Replication ETF

占比0.01%

Proshares Ultra Russell 2000

占比0.01%

Global X Russell 2000 ETF

占比0.01%

iShares Russell 2000 ETF

占比0.01%

Fidelity Enhanced Small Cap ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

ADC Therapeutics SA的前五大股东是谁？



ADC Therapeutics SA 的前五大股东如下：
Redmile Group, LLC持有股份：15.67M，占总股份比例：13.93%。
HPWH TH AG持有股份：8.67M，占总股份比例：7.71%。
Point72 Asset Management, L.P.持有股份：7.76M，占总股份比例：6.90%。
Prosight Capital持有股份：10.47M，占总股份比例：9.30%。
OrbiMed Advisors, LLC持有股份：5.91M，占总股份比例：5.25%。